These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26865514)

  • 1. Randomized, placebo-controlled trials of dichlorphenamide in periodic paralysis.
    Sansone VA; Burge J; McDermott MP; Smith PC; Herr B; Tawil R; Pandya S; Kissel J; Ciafaloni E; Shieh P; Ralph JW; Amato A; Cannon SC; Trivedi J; Barohn R; Crum B; Mitsumoto H; Pestronk A; Meola G; Conwit R; Hanna MG; Griggs RC;
    Neurology; 2016 Apr; 86(15):1408-1416. PubMed ID: 26865514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of dichlorphenamide for treatment of primary periodic paralysis.
    Sansone VA; Johnson NE; Hanna MG; Ciafaloni E; Statland JM; Shieh PB; Cohen F; Griggs RC
    Muscle Nerve; 2021 Sep; 64(3):342-346. PubMed ID: 34129236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for periodic paralysis.
    Sansone V; Meola G; Links TP; Panzeri M; Rose MR
    Cochrane Database Syst Rev; 2008 Jan; (1):CD005045. PubMed ID: 18254068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dichlorphenamide: A Review in Primary Periodic Paralyses.
    Greig SL
    Drugs; 2016 Mar; 76(4):501-7. PubMed ID: 26941026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis.
    Tawil R; McDermott MP; Brown R; Shapiro BC; Ptacek LJ; McManis PG; Dalakas MC; Spector SA; Mendell JR; Hahn AF; Griggs RC
    Ann Neurol; 2000 Jan; 47(1):46-53. PubMed ID: 10632100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Dichlorphenamide for Primary Periodic Paralysis in Adolescents Compared With Adults.
    Ciafaloni E; Cohen F; Griggs R
    Pediatr Neurol; 2019 Dec; 101():43-46. PubMed ID: 31570296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of familial hypokalemic paralysis with carbon dioxide anhydrase inhibitors].
    Kold A
    Ugeskr Laeger; 1986 Jul; 148(28):1764-5. PubMed ID: 3750476
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of "permanent" muscle weakness in familial Hypokalemic Periodic Paralysis.
    Dalakas MC; Engel WK
    Muscle Nerve; 1983; 6(3):182-6. PubMed ID: 6855804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Marked reduction in paralytic attacks in a patient with Andersen-Tawil syndrome switched from acetazolamide to dichlorphenamide.
    Gupta A; Iyadurai S; Roggenbuck J; LoRusso S
    Neuromuscul Disord; 2021 Jul; 31(7):656-659. PubMed ID: 34078557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of the Diagnosis and Treatment of Periodic Paralysis.
    Statland JM; Fontaine B; Hanna MG; Johnson NE; Kissel JT; Sansone VA; Shieh PB; Tawil RN; Trivedi J; Cannon SC; Griggs RC
    Muscle Nerve; 2018 Apr; 57(4):522-530. PubMed ID: 29125635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diclofenamid in paroxysmal hypokalemic paralysis].
    Sander C
    Dtsch Med Wochenschr; 1986 Oct; 111(41):1580. PubMed ID: 3769798
    [No Abstract]   [Full Text] [Related]  

  • 12. Episodic Muscle Disorders.
    Sansone VA
    Continuum (Minneap Minn); 2019 Dec; 25(6):1696-1711. PubMed ID: 31794467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbonic anhydrase inhibitors ameliorate the symptoms of hypokalaemic periodic paralysis in rats by opening the muscular Ca2+-activated-K+ channels.
    Tricarico D; Mele A; Conte Camerino D
    Neuromuscul Disord; 2006 Jan; 16(1):39-45. PubMed ID: 16368240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Periodic paralysis. Clinical analysis in 20 patients].
    Tengan CH; De Oliveira AS; Gabbai AA
    Arq Neuropsiquiatr; 1994 Dec; 52(4):501-9. PubMed ID: 7611943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A newly approved drug for a rare group of diseases: Dichlorphenamide for periodic paralysis.
    Fontaine B; Phillips LH
    Neurology; 2016 Apr; 86(15):1366-1367. PubMed ID: 26865522
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased sarcolemma chloride conductance as one of the mechanisms of action of carbonic anhydrase inhibitors in muscle excitability disorders.
    Altamura C; Fonzino A; Tarantino N; Conte E; Liantonio A; Imbrici P; Carratù MR; Pierno S; Desaphy JF
    Exp Neurol; 2021 Aug; 342():113758. PubMed ID: 33991525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dichlorphenamide (Keveyis) for periodic paralysis.
    Med Lett Drugs Ther; 2016 Apr; 58(1492):50. PubMed ID: 27049510
    [No Abstract]   [Full Text] [Related]  

  • 18. Drug repurposing in skeletal muscle ion channelopathies.
    Altamura C; Saltarella I; Campanale C; Laghetti P; Desaphy JF
    Curr Opin Pharmacol; 2023 Feb; 68():102329. PubMed ID: 36512979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient tolerance to carbonic anhydrase inhibitors.
    Lichter PR; Newman LP; Wheeler NC; Beall OV
    Am J Ophthalmol; 1978 Apr; 85(4):495-502. PubMed ID: 655230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypokalemic periodic paralysis exacerbated by acetazolamide.
    Torres CF; Griggs RC; Moxley RT; Bender AN
    Neurology; 1981 Nov; 31(11):1423-8. PubMed ID: 7031501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.